SCHEMBL4690020

SCHEMBL4690020

C[C@@H]1c2c(c(O)c3ncccc3c2N(C)S(C)(=O)=O)C(=O)N1Cc1ccc(F)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
COMT P21964 3/20 0.38
CNR2 P34972 4/20 0.36
CNR1 P21554 1/20 0.36
KDM4E B2RXH2 3/20 0.35
MAPT P10636 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
LMNA P02545 1/20 0.35
HSP90AA1 P07900 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TACR1 P25103 3/20 0.35
KAT2B Q92831 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4693921 1.00 COMT (0.38) COMTCNR2CNR1KDM4EMAPT
SCHEMBL4690017 1.00 COMT (0.38) COMTCNR2CNR1KDM4EMAPT
SCHEMBL4690940 0.91 COMT (0.38) COMTCNR2CNR1KDM4EMAPT
SCHEMBL14270415 0.91 COMT (0.38) COMTCNR2CNR1KDM4EMAPT
SCHEMBL14573799 0.90 CYP2C19 (0.37) CNR2CNR1KDM4EMAPTCYP1A2
SCHEMBL4693904 0.83 MAPK1 (0.32) KDM4EMAPTCYP1A2CYP2C19CYP3A4
SCHEMBL4693900 0.83 MAPK1 (0.32) KDM4EMAPTCYP1A2CYP2C19CYP3A4
SCHEMBL14573710 0.83 MAPK1 (0.32) KDM4EMAPTCYP1A2CYP2C19CYP3A4
SCHEMBL4693897 0.83 MAPK1 (0.32) KDM4EMAPTCYP1A2CYP2C19CYP3A4
SCHEMBL4694444 0.83 TSHR (0.41) CNR2CNR1KDM4EMAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888581-A2 HIV-INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2008-02-20 EP disclosed
US-20070072831-A1 Integrase inhibitor compounds GILEAD SCIENCES, INC. 2007-03-29 US disclosed
US-20070072831-A1 Integrase inhibitor compounds GILEAD SCIENCES, INC. 2007-03-29 US disclosed
US-20070072831-A1 Integrase inhibitor compounds GILEAD SCIENCES, INC. 2007-03-29 US disclosed
WO-2006125048-A2 HIV-INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072831-A1 Integrase inhibitor compounds TYMP, CDKN1A, PAICS COMT 645/4885CNR2 4717/4885CNR1 4589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.